Tuesday, June 30, 2015

Federal appeals court sides with Teva and Par, against BASF-Pronovo and GSK

Teva Pharmaceuticals USA and Par Pharmaceutical Co., won a federal appeals court patent infringement decision posted Thursday, which - pending FDA approval - will allow the generic drug companies to make cheaper versions of the omega-3 fish oil drug Lovaza, which is sold in the United States by GlaxoSmithKline.

Federal appeals court sides with Teva and Par, against BASF-Pronovo and GSK

0 comments
Lovaza
Lovaza

Teva Pharmaceuticals USA and Par Pharmaceutical Co., won a federal appeals court patent infringement decision posted Thursday, which - pending FDA approval - will allow the generic drug companies to make cheaper versions of the omega-3 fish oil drug Lovaza, which is sold in the United States by GlaxoSmithKline.

Lovaza is meant to treat high levels of triglycerides, which can be factor in heart disease.

Teva is based in Israel but has its Americas headquarters in North Wales, Montgomery County. GSK is based in London, but has operations in Philadelphia and the surrounding region.

BASF, the German chemical giant, owns the active ingredient in Lovaza after buying 98 percent of Pronovo in January of 2013.

Through licensing deals, Pronovo had sold the drug in more than 50 countries. Abbott sells the drug in Europe, for example. But the sales in United States and Puerto Rico generated $916 million for GSK in 2011 and $959.5 million in 2012.

The three-judge panel for the U.S. Court of Appeals for the Federal Circuit overturned a Delaware federal court decision, finding that one key patent had already been made available for public use and a second had expired.

GSK issued a statement on Friday that did little more than acknowledge the appeals court decision.

"Lovaza remains available and GSK is not aware that the Food and Drug Administration (FDA) has approved any generic copies to date," GSK said in its statement.

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter